Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.38 |
| ▸ | BCL6 | P41182 | 3/20 | 0.37 |
| ▸ | BCOR | Q6W2J9 | 3/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.34 |
| ▸ | PDE4A | P27815 | 5/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29246338 | 0.75 | BCL6 (0.45) | BCL6BCORSYKKAT2BBAZ2B | |
| SCHEMBL31508019 | 0.73 | GPR119 (0.37) | SCD | |
| SCHEMBL2031745 | 0.71 | MEN1 (0.46) | POLB | |
| SCHEMBL31383842 | 0.71 | KAT2B (0.43) | BCL6BCORSYKKAT2BBAZ2B | |
| SCHEMBL3805044 | 0.71 | SCD (0.53) | BCL6BCORKAT2BBAZ2BSCD | |
| SCHEMBL1611708 | 0.69 | BCL6 (0.45) | BCL6BCORSYKKAT2BBAZ2B | |
| SCHEMBL19174929 | 0.69 | BCL6 (0.50) | BCL6BCORSYK | |
| SCHEMBL4161984 | 0.68 | ALDH1A1 (0.40) | — | |
| SCHEMBL16751204 | 0.68 | BCL6 (0.44) | TXNRD1BCL6BCORPOLB | |
| SCHEMBL18691116 | 0.68 | KAT2B (0.39) | TXNRD1BCL6BCORSYKKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TXNRD1 1946/4885BCL6 1608/4885BCOR 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.